Skip to content
Triveni Bio
News

The latest company updates, news, and insights

Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis

Press Release
5.21.2025

Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders

Press Release
10.2.2024

BioPharmaDive News: With $115M more, Triveni accelerates immune drug work

In the News
10.2.2024

FierceBiotech News: Triveni ropes in $115M series B less than a year after $92M fundraise

In the News
10.2.2024

Stifel 2024 Virtual Immunology and Inflammation Summit

In the News
9.18.2024

Triveni Bio Appoints Bhaskar Srivastava, M.D., Ph.D., as Chief Medical Officer, Announces Key Program Updates

Press Release
6.12.2024

Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors

Press Release
12.13.2023

MedCity News: Biotech Startup Triveni Unveils $92M to Address Barrier to Treating Inflammation

In the News
11.5.2023

Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders

Press Release
10.26.2023

BioPharma Dive: Triveni emerges from biotech merger with $92M for immune disease drugs

In the News
10.26.2023
Top